Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite

Revenues Also Down Following Latest Revisions

Dec 17 2020

• By Dean Rudge

Japan — The latest price revisions of the NHI prices were conducted in April. • Source: Shutterstock

Related Content

Nichi-Iko Delays US Infliximab Amid Coronavirus Outbreak

May 27 2020

Teva Shifts Strategy In Japan

Jul 30 2020

Related Companies

Nichi-Iko Pharmaceutical Co., Ltd.

Additional Topics

Japan Asia Pacific United States Sales & Earnings Strategy Biosimilars BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.